[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07352592":3,"trial-entities:NCT07352592":107,"trial-summary:NCT07352592":110},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":29,"interventions":32,"primary_outcomes":39,"secondary_outcomes":47,"sex":63,"minimum_age":64,"maximum_age":65,"healthy_volunteers":66,"eligibility_criteria":67,"std_ages":75,"locations":78,"central_contacts":100,"overall_officials":103,"references":105,"see_also_links":106},"NCT07352592","IRB-300015520","Process-Based Approach Case Series For Anxiety Problems","PBT For Anxiety Problems","RECRUITING","2030-12-31","2026-06","2026-06-12","2026-06-01","University of Alabama at Birmingham","OTHER",false,"A case series of PBA intervention for anxiety problems.","Participants will self-refer to this study by emailing a research assistant (Mr. Whittington).\n\nThey will then attend a screening session where they complete an informed consent form and are assessed for inclusion\u002Fexclusion criteria. During the screening the research assistant will conduct a clinical interview and collaboratively identify hypothetical processes (e.g. avoidance) that might be contributing to the participants anxiety symptoms. Together, they will identify 8-items from the process-based assessment tool (see survey) that might be relevant to the participants anxiety.\n\nParticipants will then complete a baseline survey battery on a lab computer (via Qualtrics; \\~20 minutes).\n\nParticipants will then complete a two-week assessment period where they complete brief (\\\u003C2 minute) surveys five times a day (approximately 9 am, noon, 2 pm, 5 pm, and 8 pm) each day for the two weeks. These surveys will be sent to participants' phone via Qualtrics. These surveys will be the 8-items identified during the intake session, with one additional item assessing momentary anxiety and an additional item assessed momentary quality of life perception.\n\nThe research team will use the data gathered during the two-week assessment period to create personalized networks of processes leading to participant anxiety symptoms. Each participants' network will guide their therapy treatment.\n\nParticipants will then attend up to 25 sessions of counseling for their anxiety. Sessions will occur roughly weekly and will last approximately 50 minutes. All sessions will occur in Dr. Borgogna's lab and clinic space (Campbell Hall Ste 310) on the UAB campus. The therapists in the study will all be masters-level clinicians in the UAB medical\u002Fclinical psychology program preparing for licensure (Mr. Whittington, Mr. Johnson, and Ms. Jafari) or a licensed clinical psychologist (Dr. Borgogna). Therapy sessions for pre-licensed clinicians will be recorded onto a UAB computer in Dr. Borgogna's lab and reviewed for supervision purposes by Dr. Borgogna (A\u002FV recordings not for research purposes). Recordings will be deleted within 30 days of each therapy session.\n\nParticipants will complete the main battery again at post-test.",[19],"Anxiety",[21,22,23,24,19],"PBT","PBA","Process-Based Approach","Process-Based Cognitive Behavioral Therapy","INTERVENTIONAL","TREATMENT",[28],"NA",{"count":30,"type":31},10,"ESTIMATED",[33],{"type":34,"name":23,"description":35,"armGroupLabels":36,"otherNames":38},"BEHAVIORAL","Process-Based Approaches (PBA) were developed to improve psychotherapy outcomes. Early writings referred to PBA as process-based therapy or process-based cognitive behavioral therapy. The current nomenclature was adopted to distinguish PBA as a unifying approach that incrementally builds on clinical psychological science rather than a manualized treatment protocol. PBA provides a framework for flexibly applying evidence-based techniques from multiple therapeutic traditions to target hypothesized psychological processes that give rise to individual patient presentations. Each patient is conceptualized independently, and intervention structure may vary substantially based on need, while retaining empirically supported tools. This contrasts with disorder-specific treatment manuals, which assume homogeneity despite substantial variability in underlying processes (e.g., anxiety).",[37],"Process-based approach",[21],[40,44],{"measure":41,"description":42,"timeFrame":43},"Generalized Anxiety Disorder-7","Anxiety scale","From enrollment to the end of treatment, up to 25 weeks.",{"measure":45,"description":46,"timeFrame":43},"Beck Anxiety Inventory","Anxiety Measure",[48,51,54,57,60],{"measure":49,"description":50,"timeFrame":43},"Patient Health Questionnaire-9","Depression measure",{"measure":52,"description":53,"timeFrame":43},"Experiential Avoidance Rating Scale","Experiential avoidance measure",{"measure":55,"description":56,"timeFrame":43},"Quality of Life Scale","Quality of Life Measure",{"measure":58,"description":59,"timeFrame":43},"Big Five Inventory","Measure of Personality",{"measure":61,"description":62,"timeFrame":43},"PSY-Flex","Psychological flexibility measure","ALL","18 Years",null,true,{"inclusion":68,"exclusion":71,"raw_text":74},[69,70],"Score on GAD-7 \\>10 at baseline","Access to mobile device",[72,73],"Current psychotherapy treatment","Current\u002Fpast severe psychopathology (e.g., history of psychosis, suicide attempt or self-injury within the past 12 months, narcotics use within the past 3 months)","Inclusion Criteria:\n\n* Score on GAD-7 \\>10 at baseline\n* Access to mobile device\n\nExclusion Criteria:\n\n* Current psychotherapy treatment\n* Current\u002Fpast severe psychopathology (e.g., history of psychosis, suicide attempt or self-injury within the past 12 months, narcotics use within the past 3 months)",[76,77],"ADULT","OLDER_ADULT",[79],{"facility":80,"status":8,"city":81,"state":82,"zip":83,"country":84,"contacts":85,"geoPoint":97},"University of Alabama at Birmingham Dr. Borgogna's lab","Birmingham","Alabama","35233","United States",[86,91,94],{"name":87,"role":88,"phone":89,"email":90},"Nicholas Borgogna, PhD","CONTACT","(205) 934-3850","borgogna@uab.edu",{"name":92,"role":88,"phone":89,"email":93},"Drew Whittington MS (Research Coordinator), MS","whitdrew@uab.edu",{"name":95,"role":96},"Nicholas C Borgogna, PhD","PRINCIPAL_INVESTIGATOR",{"lat":98,"lon":99},33.52066,-86.80249,[101],{"name":102,"role":88,"phone":89,"email":93},"Damion D Whittinton, MS",[104],{"name":95,"affiliation":13,"role":96},[],[],{"nct_id":4,"conditions":108,"biomarkers":109},[19],[],{"nct_id":4,"found":15,"summary":65,"prompt_version":65}]